---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-033973"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2024-02-13T23:59:59+00:00"
generated_at: "2026-06-06T03:28:44.282541+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics to raise ~$280M via sale of 3.9M common shares at $71.50/share

## Summary
- Issues 3,916,082 common shares at $71.50 per share to institutional investors.
- Gross proceeds of approximately $280 million; offering not underwritten, direct to investors.
- Shares offered under existing shelf registration statement (Form S-3, filed July 2021).
- Closing expected within ten trading days after February 13, 2024.

## SEC filing metadata
- accession: 0001193125-24-033973
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2024-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000119312524033973/0001193125-24-033973-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000119312524033973/d788919d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-033973
- JSON: https://secwatch.observer/filing/0001193125-24-033973.json
- Plain text: https://secwatch.observer/filing/0001193125-24-033973.txt

## Key facts
- Material Agreements
  CRISPR Therapeutics AG entered into Investment Agreement with certain institutional investors valued at $280 million (effective 2024-02-13).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: $280 million
  - Effective: 2024-02-13
  source text: On February 13, 2024, CRISPR Therapeutics AG (the “Company”) entered into an investment agreement (the “Investment Agreement”) with certain institutional investors relating to the issuance of 3,916,082 shares of the Company’s common shares, par value of CHF 0.03 per share (the “Common Shares”), to such investors (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674416/000119312524033973/0001193125-24-033973-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.